ALC vs SYRE
Alcon Inc vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
67
Insufficient Data
| Metric | ALC | SYRE |
|---|
| AI Score |
68
|
67
|
| Price |
$75.39
|
$102.72
|
| P/E Ratio |
45.39×
|
-52.69×
|
| ROE |
4.4%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
54.9%
|
0.0%
|
| Debt / Equity |
0.24×
|
0.00×
|
| Dividend Yield |
0.5%
|
0.0%
|
| RSI (14) |
73.4
|
53.3
|
| Beta |
0.703
|
3.026
|
| Expected Upside |
+11.3%
|
—
|
AI Committee View
Current Innellis committee reasoning for ALC versus SYRE.
ALC leads by 1 points.
ALC scores 68/100 (Buy) versus SYRE at 67/100 (Insufficient Data).
ALC Committee View
75% agreement
4 analysts
The primary driver is quarter-over-quarter growth rate is accelerating, not just positive. The main limiting factor is rsi at 73 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- RSI at 73 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
SYRE Committee View
100% agreement
3 analysts
The primary driver is vix regime is low -- calm backdrop supports risk-taking. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 77 -- overbought on the larger timeframe too — Technical